C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Report 2024

The C-X-C chemokine receptor 4 (CXCR4) antagonist market size has grown strongly in recent years. It will grow from $1.49 billion in 2023 to $1.62 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The historic period's growth can be attributed to greater transparency in clinical trial data, patient-centric healthcare policies, a rising prevalence of chemotherapy resistance, policies focusing on patient-centered care and accessibility, and a growing preference for targeted therapies.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth in the forecast period is driven by expanding applications in HIV or AIDS, increasing demand for stem cell mobilization, potential benefits in autoimmune diseases, growth in biobanking initiatives, and the integration of artificial intelligence (AI) in drug discovery. Key trends during this period include a heightened focus on orphan drug development, the creation of combination therapies, the adoption of precision oncology methods, the expansion of clinical trials for new therapies, and advancements in drug delivery technologies.

The rise in human immunodeficiency virus (HIV) prevalence is expected to drive growth in the spasmodic dysphonia treatment market. HIV, a virus that targets and weakens the immune system by attacking CD4 (T) cells, can lead to AIDS if untreated. The increasing prevalence of HIV is due to factors such as low awareness, limited healthcare access, high transmission rates, and inadequate prevention in some regions. CXCR4 antagonists help manage HIV by blocking the CXCR4 receptor, preventing the virus from accessing and infecting immune cells, thus aiding in controlling the virus and enhancing immune response. For instance, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7 million] people living with HIV globally, with 1.3 million [1 million-1.7 million] new infections that year. Consequently, the growing prevalence of HIV is fueling the expansion of the CXCR4 antagonist market.

Leading companies in the CXCR4 antagonist market are focusing on developing bioequivalents to improve treatment options and patient outcomes for various diseases. Bioequivalents are pharmaceutical products that have similar bioavailability when compared under similar conditions. For example, in May 2024, Gland Pharma, an India-based generic injectable manufacturer, received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection. This product is bioequivalent and therapeutically equivalent to the reference drug, MOZOBIL (plerixafor) injection by Genzyme Corporation. Plerixafor is a CXCR4 antagonist used in conjunction with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

In April 2024, PANTHERx, a US-based specialty pharmacy, partnered with X4 Pharmaceuticals Inc. to facilitate the distribution of XOLREMDI (mavorixafor). This oral treatment, taken once daily, selectively antagonizes the CXCR4 receptor and was approved by the U.S. Food and Drug Administration (FDA). It is the first FDA-approved therapy specifically indicated for patients aged 12 and older with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. X4 Pharmaceuticals Inc., a US-based late-stage clinical biopharmaceutical company, focuses on developing and commercializing novel therapeutics, including CXCR4 antagonists such as XOLREMDI (mavorixafor).

Major companies operating in the C-X-C chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc., F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc., Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4 Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.

North America was the largest region in the C-X-C chemokine receptor type 4 antagonists market in 2023. The regions covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

C-X-C chemokine receptor 4 (CXCR4) antagonists are pharmaceutical compounds aimed at inhibiting the CXCR4 receptor, which is found on the surface of specific cells. These antagonists function by blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as SDF-1), a key player in cell migration, hematopoiesis, and immune responses.

The main types of CXCR4 antagonists include BL-8040, GMI-1359, plerixafor (AMD3100), balixafortide (POL6326), USL311, burixafor (GPC-100), and others. These antagonists can be administered orally or via injection. BL-8040, for example, is a synthetic peptide developed to block CXCR4, which is involved in cancer cell migration and survival. The product pipelines feature both approved clinical trials and pre-clinical trials for a range of applications, including cancer, human immunodeficiency virus (HIV), chronic inflammatory diseases, stem cell mobilization, and immune and autoimmune diseases. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market research report is one of a series of new reports that provides C-X-C chemokine receptor 4 (CXCR4) antagonist market statistics, including C-X-C chemokine receptor 4 (CXCR4) antagonist industry global market size, regional shares, competitors with a C-X-C chemokine receptor 4 (CXCR4) antagonist market share, detailed C-X-C chemokine receptor 4 (CXCR4) antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the C-X-C chemokine receptor 4 (CXCR4) antagonist industry. This C-X-C chemokine receptor 4 (CXCR4) antagonist market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market consists of sales of TN14003 (Trogarzo), X4P-001 (Mavorixafor), TG-0054, and KRH-3955. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.